Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 7/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.42 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.42 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4686165 | 1.00 | NFE2L2 (0.49) | NFE2L2MEN1NPC1AGTR1KMT2A | |
| SCHEMBL4679776 | 0.87 | NFE2L2 (0.44) | NFE2L2MEN1NPC1AGTR1KMT2A | |
| SCHEMBL4679780 | 0.87 | NFE2L2 (0.44) | NFE2L2MEN1NPC1AGTR1KMT2A | |
| SCHEMBL9714159 | 0.85 | NFE2L2 (0.64) | NFE2L2CYP1A1CYP1A2CYP1B1PRMT1 | |
| SCHEMBL28250254 | 0.85 | NFE2L2 (0.64) | NFE2L2CYP1A1CYP1A2CYP1B1PRMT1 | |
| SCHEMBL4686097 | 0.81 | NFE2L2 (0.59) | NFE2L2CYP1A1CYP1A2KDM4EPTPN1 | |
| SCHEMBL4686100 | 0.81 | NFE2L2 (0.59) | NFE2L2CYP1A1CYP1A2KDM4EPTPN1 | |
| SCHEMBL4683638 | 0.80 | CA1 (0.53) | NFE2L2NPC1CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL14501345 | 0.77 | NFE2L2 (0.54) | NFE2L2MEN1KMT2ACYP1A1CYP1A2 | |
| SCHEMBL14143273 | 0.77 | NFE2L2 (0.54) | NFE2L2MEN1KMT2ACYP1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1386913-B1 | PYRROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO (JP) | 2008-07-16 | — | — | EP | disclosed |
| EP-1386913-B1 | PYRROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO (JP) | 2008-07-16 | — | — | EP | disclosed |
| US-7220773-B2 | Heterocylic amines used as antidiabetic or hyperglycemic agents | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| US-7220773-B2 | Heterocylic amines used as antidiabetic or hyperglycemic agents | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| US-7220773-B2 | Heterocylic amines used as antidiabetic or hyperglycemic agents | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| US-20040162331-A1 | Pyrrole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-08-19 | — | — | US | disclosed |
| EP-1386913-A1 | PYRROLE DERIVATIVE | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162331-A1 | Pyrrole derivative | SLC5A1, GLP1R, SLC5A2 | NFE2L2 1885/4885MEN1 3286/4885NPC1 2030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.